Assertio Holdings, Inc.ASRTEarnings & Financial Report
Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA). On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As o...
ASRT Q3 2025 Key Financial Metrics
Revenue
$49.5M
Gross Profit
N/A
Operating Profit
$11.5M
Net Profit
$11.4M
Gross Margin
N/A
Operating Margin
23.2%
Net Margin
23.1%
YoY Growth
69.4%
EPS
$0.11
Financial Flow
Assertio Holdings, Inc. Q3 2025 Financial Summary
Assertio Holdings, Inc. reported revenue of $49.5M for Q3 2025, with a net profit of $11.4M (23.1% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $49.5M |
|---|---|
| Net Profit | $11.4M |
| Gross Margin | N/A |
| Operating Margin | 23.2% |
| Report Period | Q3 2025 |
Assertio Holdings, Inc. Annual Revenue by Year
Assertio Holdings, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $125.0M).
| Year | Annual Revenue |
|---|---|
| 2024 | $125.0M |
| 2023 | $152.1M |
| 2022 | $156.2M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $33.0M | $32.4M | $31.1M | $29.2M | $32.2M | $26.5M | $29.2M | $49.5M |
| YoY Growth | -34.5% | -23.6% | -24.1% | -18.0% | -2.4% | -18.4% | -6.1% | 69.4% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $286.4M | $282.0M | $279.4M | $276.0M | $284.7M | $286.4M | $273.8M | $319.8M |
| Liabilities | $148.4M | $147.5M | $147.3M | $145.5M | $163.7M | $177.9M | $180.5M | $214.0M |
| Equity | $138.0M | $134.5M | $132.2M | $130.5M | $121.1M | $108.5M | $93.3M | $105.8M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $5.7M | $7.5M | $7.4M | $-35000 | $11.5M | $-12.5M | $19.1M | $-4.8M |
More Companies
AZN
ASTRAZENECA PLC
Revenue
$14.5B
Net Profit
$2.4B
NVS
NOVARTIS AG
NVO
NOVO NORDISK A S
SNY
Sanofi
GSK
GSK plc
TAK
TAKEDA PHARMACEUTICAL CO LTD
ARGX
ARGENX SE
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Revenue
$1.1B
Net Profit
$186.4M
ALC
ALCON INC
Revenue
$2.6B
Net Profit
$176.0M
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Revenue
$4.7B
Net Profit
$481.0M